Dr. Lauren Elreda, MD

Dr. Elreda practices at NewYork-Presbyterian Queens in Flushing, New York, part of NewYork-Presbyterian Hospital.

Dr. Elreda's NPI, 1952479073, was assigned on November 30, 2006. Dr. Elreda graduated from Ross University School of Medicine in 2003. Dr. Elreda's New Jersey license number on file is MA082309.

Dr. Elreda's primary practice is NewYork-Presbyterian Queens, at 56-45 Main Street, Flushing, NY 11355 in Queens County. The practice phone is (718) 670-2000.

Dr. Elreda's primary practice is NewYork-Presbyterian Queens in Flushing, New York, part of NewYork-Presbyterian Hospital. The medical group on file is NewYork-Presbyterian Medical Group Queens. Dmand AI also links Dr. Elreda to 1 more dialysis center, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Elreda practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Elreda's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Elreda is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Elreda's licenses on file in 2 states: New Jersey and New York.

Dmand AI lists breast cancer, chronic anemia, lung cancer, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Elreda treats.

CMS data shows 437 Medicare services from Dr. Elreda across 5 procedure codes in 2024, for 208 Medicare patients. Medicare paid $38,856 for them.

CMS counts 208 Medicare patients who saw Dr. Elreda in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have cancer, and 75% have high blood pressure. 29% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Elreda's median patient age at 70, with 82% women.

In 2024, Dr. Elreda wrote 642 Medicare Part D claims for 230 patients. 92% of them were for generic drugs. CMS names the drug for 514 of them, across 8 drugs with 11 or more claims each, at $398,932 in total drug cost. In 2023, CMS named 495 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Elreda for performance year 2024, reported through an alternative payment model (APM). Dr. Elreda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Elreda, published from 2014 to 2024. 2022 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, COVID-19 and New York City. Dr. Elreda's most frequent co-authors are Manmeet K. Malik, DO, Evelyn O. Taiwo, MD and Juliet Brause Aizer, MD, MPH.

CMS Open Payments shows 40 general payments to Dr. Elreda from 23 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 86% of the total. Abbvie Inc. paid the most, $148.

Dmand AI lists 2 awards for Dr. Elreda, most recently Exceptional Women in Medicine in 2025.

Dr. Elreda graduated from Ross University School of Medicine in 2003.

Dr. Elreda is in network with 18 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.